Cystic Fibrosis (CF)
ReCode is developing RCT2100, an inhaled disease-modifying mRNA-based investigational therapy for CF that focuses specifically on the 10 to 13 percent of CF patients who have nonsense mutations and do not respond to currently approved CFTR modulators.
Primary Ciliary Dyskinesia (PCD)
ReCode is developing RCT1100, an inhaled disease-modifying mRNA-based investigational therapy for the treatment of PCD caused by mutations in DNAI1, an essential gene for ciliary movement.
Opportunities in a Wide Array of Genetic Diseases
With the versatility of genetic cargo and flexibility in administration, ReCode’s SORT LNP technology has potential applications across a broad range of genetically defined rare diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.
(PCD) mRNA DNAI1 Inhaled
(CF) mRNA CFTR Inhaled
Surfactant deficiencies mRNA Undisclosed IV
spleen Vaccines mRNA Undisclosed IM
liver Alpha-1 antitrypsin Gene correction SERPINA1 IV
cns Various Multiple Undisclosed Intrathecal